Ultragenyx Pharmaceutical Inc. (RARE)
$14.92-2.48%Close
BUYRECOVERY · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.5B
- Beta
- 0.32
- P/E (TTM)
- -2.55
- IV ATM
- 59.4%
- Short % float
- 21.53%
- Days to cover
- 3.1
- SI change
- +22.8%
- 1W
- +3.18%
- 1M
- +9.63%
- vs SPY 1W
- +3.32%
- vs SPY 1M
- +7.12%
Industry peers
FMP comparable companies · ranked by market cap
- BBIOSELLBridgeBio Pharma, Inc.$12.8BRECOVERYQ 18$65.35-3.73%
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.80-1.82%
- PTCTSELLPTC Therapeutics, Inc.$5.4BCRISISQ 18$64.70-4.77%
- QURESELLuniQure N.V.$1.6BCRISISQ 16$22.59-2.56%
- MGTXSELLMeiraGTx Holdings plc$990MCRISISQ 6$10.69-4.24%
- FDMTSELL4D Molecular Therapeutics, Inc.$697MRECOVERYQ 3$13.33-4.92%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on RARE?
- LOPJLB’s latest quantitative signal on Ultragenyx Pharmaceutical Inc. (RARE) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is RARE in?
- Ultragenyx Pharmaceutical Inc. (RARE) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Ultragenyx Pharmaceutical Inc. (RARE) do?
- Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody …